SCHEMBL4293136

SCHEMBL4293136

O=Cc1ccc(OCCc2ccccc2)c(OCCOc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.54
MAPT P10636 5/20 0.52
ALDH1A1 P00352 5/20 0.52
HPGD P15428 4/20 0.52
NPSR1 Q6W5P4 2/20 0.51
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HTT P42858 1/20 0.51
AKR1C3 P42330 1/20 0.49
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
CYP2C9 P11712 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
TTR P02766 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 2/20 0.45
CASP6 P55212 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4576841 0.93 FDPS (0.57) FDPSMAPTALDH1A1HPGDNPSR1
SCHEMBL5213944 0.87 TACR2 (0.54) FDPSMAPTALDH1A1NPSR1LMNA
SCHEMBL9077155 0.87 TACR2 (0.54) FDPSMAPTALDH1A1NPSR1LMNA
SCHEMBL29721221 0.87 TACR2 (0.54) FDPSMAPTALDH1A1NPSR1LMNA
SCHEMBL7141110 0.85 FDPS (0.55) FDPSMAPTALDH1A1HPGDNPSR1
SCHEMBL30467215 0.85 FDPS (0.55) FDPSMAPTALDH1A1HPGDNPSR1
SCHEMBL9078005 0.84 FDPS (0.72) FDPSMAPTALDH1A1HPGDNPSR1
SCHEMBL6229249 0.84 FDPS (0.63) FDPSMAPTALDH1A1HPGDNPSR1
SCHEMBL31331562 0.84 FDPS (0.72) FDPSMAPTALDH1A1HPGDNPSR1
SCHEMBL21427194 0.84 FDPS (0.54) FDPSMAPTALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954815-B1 PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION GLYCOFI INC (US) 2015-02-25 EP disclosed
US-8795984-B2 Production of glycoproteins with reduced O-glycosylation MERCK SHARP & DOHME CORP. (US) 2014-08-05 US disclosed
US-8501438-B2 Production of glycoproteins with reduced O-glycosylation GLYCOFI, INC. (US) 2013-08-06 US disclosed
US-20120322101-A1 PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION GLYCOFI, INC. (US) 2012-12-20 US disclosed
US-20120237973-A1 PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION GLYCOFI, INC. (US) 2012-09-20 US disclosed
US-8206949-B2 Production of glycoproteins with reduced O-glycosylation GLYCOFI, INC. (US) 2012-06-26 US disclosed
US-20090170159-A1 PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION GLYCOFI, INC (US) 2009-07-02 US disclosed
EP-1954815-A2 PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION Glycofi, Inc. (US) 2008-08-13 EP disclosed
WO-2007061631-A2 PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION GLYCOFI, INC (US) 2007-05-31 WO disclosed
EP-1313471-B1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS UCB SA (BE) 2007-04-11 EP disclosed
US-7105554-B2 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2006-09-12 US disclosed
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD (GB) 2004-01-08 US disclosed
EP-1313471-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002017915-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents SLC5A2, OXSR1, SLC5A1 FDPS 2387/4885MAPT 4658/4885ALDH1A1 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.